Immunome Inc (NASDAQ: IMNM)’s stock price has plunge by -3.88relation to previous closing price of 11.59. Nevertheless, the company has seen a -11.16% plunge in its stock price over the last five trading sessions. zacks.com reported 2024-11-13 that Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.
Is It Worth Investing in Immunome Inc (NASDAQ: IMNM) Right Now?
The 36-month beta value for IMNM is also noteworthy at 1.78. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMNM is 48.99M, and at present, short sellers hold a 21.37% of that float. The average trading volume of IMNM on November 15, 2024 was 602.77K shares.
IMNM’s Market Performance
The stock of Immunome Inc (IMNM) has seen a -11.16% decrease in the past week, with a -9.72% drop in the past month, and a -17.66% fall in the past quarter. The volatility ratio for the week is 7.50%, and the volatility levels for the past 30 days are at 5.81% for IMNM. The simple moving average for the past 20 days is -8.83% for IMNM’s stock, with a -31.35% simple moving average for the past 200 days.
Analysts’ Opinion of IMNM
Many brokerage firms have already submitted their reports for IMNM stocks, with Stephens repeating the rating for IMNM by listing it as a “Overweight.” The predicted price for IMNM in the upcoming period, according to Stephens is $30 based on the research report published on November 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see IMNM reach a price target of $27. The rating they have provided for IMNM stocks is “Overweight” according to the report published on May 31st, 2024.
JP Morgan gave a rating of “Overweight” to IMNM, setting the target price at $24 in the report published on April 30th of the current year.
IMNM Trading at -15.56% from the 50-Day Moving Average
After a stumble in the market that brought IMNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.02% of loss for the given period.
Volatility was left at 5.81%, however, over the last 30 days, the volatility rate increased by 7.50%, as shares sank -7.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.66% lower at present.
During the last 5 trading sessions, IMNM fell by -11.16%, which changed the moving average for the period of 200-days by -32.77% in comparison to the 20-day moving average, which settled at $12.22. In addition, Immunome Inc saw 4.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNM starting from Rosett Max, who sale 14,380 shares at the price of $16.01 back on Sep 19 ’24. After this action, Rosett Max now owns 47,476 shares of Immunome Inc, valued at $230,224 using the latest closing price.
Rosett Max, the Officer of Immunome Inc, proposed sale 14,380 shares at $16.01 during a trade that took place back on Sep 19 ’24, which means that Rosett Max is holding shares at $230,211 based on the most recent closing price.
Stock Fundamentals for IMNM
Current profitability levels for the company are sitting at:
- -31.34 for the present operating margin
- 0.88 for the gross margin
The net margin for Immunome Inc stands at -30.15. The total capital return value is set at -1.46. Equity return is now at value -199.56, with -155.54 for asset returns.
Based on Immunome Inc (IMNM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.98. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1579.52.
Currently, EBITDA for the company is -28.27 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 50.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.12.
Conclusion
In summary, Immunome Inc (IMNM) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
